Interleukin-23 InhibitorsEsra AdışenGazi University Faculty of Medicine, Department of Dermatology and Venereology, Ankara, Turkey
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment. Keywords: IL-23 inhibitor, guselkumab, tildrakizumab, risankizumab
İnterkökin-23 inhibitörleriEsra AdışenGazi Üniversitesi Tıp Fakültesi, Deri ve Zührevi Hastalıklar Anabilim Dalı, Ankara
Sistemik tedavi planlanan orta ve şiddetli plak tip psoriasisli erişkin hastalarda interlökin-23 (IL-23) inhibisyonu yoluyla etki eden ajanlardan FDA onayı alanlar guselkumab, tildrakizumab ve risankizumabtır. IL-23 inhibitörleri ile tedavi edilen psoriasisli olgularda tedaviye yanıt 12 haftalık tedavi sonrası değerlendirilmelidir. Kısmi yanıt veren hastalarda doz artışı planlanabilir ya da tedaviye topikal kortikosteroidler, D vitamini analogları, metotreksat, fototerapi (UVB) eklenilebilir. Anahtar Kelimeler: IL-23 inhibitörü, guselkumab, tildrakizumab, risankizumab
Esra Adışen. Interleukin-23 Inhibitors. Turkderm-Turk Arch Dermatol Venereol. 2022; 56(1): 61-66
Corresponding Author: Esra Adışen, Türkiye |
|
Full Text PDF
Print
Download citation
RIS
Share with email
Share
Send email to author
PubMed